Probiotic Supplements in Medical Conditions

Conditions with Strong Evidence Supporting Probiotic Use

The American Gastroenterological Association recommends probiotics for specific medical conditions, but benefits are highly strain-specific and cannot be generalized across all probiotic products 1, 2
Probiotics reduce the risk of necrotizing enterocolitis (NEC) in preterm infants with a relative risk of 0.43 (95% CI 0.33-0.56) and reduce all-cause mortality (RR 0.65, 95% CI 0.52-0.81) 3, 4, 5
Probiotic supplementation reduces the risk of late-onset sepsis in preterm neonates (RR 0.83), bacterial sepsis (RR 0.82), and fungal sepsis (RR 0.57) 4, 5
Lactobacillus alone or combined with Bifidobacterium preparations are effective for reducing NEC and late-onset sepsis in preterm infants 3, 4
Probiotics reduce infection episodes, shorten duration, decrease antibiotic use, and reduce school/work absences for upper respiratory tract infections 3, 4
Probiotics decrease liver aminotransferases and improve insulin resistance in non-alcoholic fatty liver disease (NAFLD) 3, 4

The American Gastroenterological Association does not recommend probiotics for acute pancreatitis due to no significant effect demonstrated 3, 4
Probiotics have insufficient quality evidence to recommend for bacterial vaginosis, urinary tract infections, depression and mental health disorders, and metabolic diseases 3, 4

The most important caveat is that benefits demonstrated for one probiotic strain cannot be extrapolated to other strains or species 1, 2
Species-specific mechanisms include vitamin synthesis and gut barrier reinforcement 1, 2
Dose- and strain-specific effects include neurological, immunologic, and biochemical actions 1, 2
No single strain possesses all known probiotic benefits 1, 2
Products should be chosen based on specific strains validated in high-quality clinical trials 1, 2

Probiotics show strong evidence of effectiveness for antibiotic-associated diarrhea in both adults and children, with specific strains like Lactobacillus rhamnosus and Saccharomyces boulardii showing particular benefit 6
Clostridium difficile-associated diarrhea can be prevented with probiotics, reducing risk by up to 64% when given alongside antibiotics 6
For constipation, Bifidobacterium lactis may improve intestinal transit, evacuation frequency, and stool consistency 6
In ulcerative colitis, probiotic treatment shows promise as both remission induction and maintenance therapy, though not effective for Crohn's disease 7
Probiotics are superior to placebo in reducing the number of upper respiratory tract infection episodes, shortening infection duration, reducing antibiotic use, and decreasing school/work absences 8
Lactobacillus reuteri may be useful in the short term as an adjunct to non-surgical periodontal treatment of chronic periodontitis, though more research is needed 9

Evidence is lacking for probiotics in treating liver diseases, vaginosis, urinary tract infections, depression, and pancreatitis 7, 9
For metabolic diseases (diabetes, dyslipidemia, obesity, hypertension), more well-conducted studies are needed to demonstrate efficacy 6

Claims for medical benefits can only be made for the specific strains in which they have been demonstrated 10
No single strain would be expected to have all the effects known to derive from probiotics 10

The probiotic market is relatively unregulated, with claims often transferred from tested products to those with material differences in formulation or manufacture 11, 10
This "probiotic umbrella" concept can be problematic, especially for conditions like inflammatory bowel disease or in immunocompromised patients 11